ReviewKidney diseases (Basel, Switzerland)2023
Role of C-Reactive Protein in Kidney Diseases.
Review in Kidney diseases (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Risk prediction models for acute kidney injury in patients with acute pancreatitis: a systematic review.BMC gastroenterology · 2026Pooled it
- Comparative efficacy of different modes of exercise on inflammatory markers in patients with chronic kidney disease: a systematic review with pairwise and network meta-analyses.Scientific reports · 2026Pooled it
- Impact of Oral Hygiene Practices in Reducing Cardiometabolic Risk, Incidence, and Mortality: A Systematic Review.International journal of environmental research and public health · 2024Pooled it
- Chronic kidney diseases and inflammation research: a bibliometric analysis.Frontiers in medicine · 2024Pooled it
- The Effect of Periodontal Therapy on Renal Function and Diabetes Control in Patients With Chronic Kidney Disease. A Randomised Controlled Clinical Trial.Journal of clinical periodontology · 2026Trial
- Hyperkalemia risk and potassium trajectory after finerenone initiation: a real-world cohort study.Clinical and experimental nephrology · 2026Observational
- Dementia risk across distinct metabolic profiles in the UK Biobank.GeroScience · 2026Article
- Burden of Systemic Inflammation Among Individuals with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease in Northern China.Cardiology and therapy · 2026Article
- Predictors of In-Hospital Mortality and Incomplete Kidney Recovery in Patients with Cirrhosis-Associated Non-Hepatorenal Syndrome Acute Kidney Injury: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Association between C-reactive protein-to-platelet ratio and acute kidney injury in cardiac arrest survivors.BMC cardiovascular disorders · 2026Article
- Letter to the Editor: Early identification of mortality risk in emergency patients with chronic kidney disease - insights from India with global implications.World journal of nephrology · 2026Article
- Stage-wise variation in serum C-reactive protein and cardiovascular risk in chronic kidney disease of uncertain etiology among Sri Lankans; a preliminary study.BMC research notes · 2026Article
- Predicting anemia treatment outcomes in maintenance hemodialysis patients using multiple machine learning models.BMC medical informatics and decision making · 2026Article
- Article
- Associations of C-reactive protein, triglyceride-glucose index, and the C-reactive protein-triglyceride glucose index with multistate trajectories in the cardiovascular-renal-diabetes cluster.Frontiers in endocrinology · 2026Article
- Association between inflammatory burden index combined with D-dimer and acute kidney injury in elderly patients.Frontiers in medicine · 2026Article
- Coagulation is associated with renal function decline and chronic kidney disease in people living with HIV in South Africa.Frontiers in nephrology · 2026Article
- Association of the C-Reactive Protein-Albumin-Lymphocyte Index with Chronic Kidney Disease: A Comprehensive Assessment Based on Inflammation, Nutrition, and Immune Status.Kidney & blood pressure research · 2026Article
- Differentiated associations of inflammatory indices with laboratory-defined organ injury/involvement and hospitalization length in pediatric respiratory tract infections.Frontiers in pediatrics · 2026Article
- High-sensitivity C-reactive protein-triglyceride-glucose composite index and reduced estimated glomerular filtration rate in adults undergoing routine health examinations: a cross-sectional study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: C-reactive protein (CRP) is an acute-phase protein and has been found to be a risk factor for acute kidney injury (AKI) and chronic kidney diseases (CKD). However, the role and mechanisms of CRP in AKI and CKD remain largely unclear. Summary: Clinically, elevated serum CRP is a risk factor or biomarker for patients with AKI and CKD. Interestingly, in critically ill COVID-19 patients, increased serum CRP is also associated with the development of AKI. Functionally, studies using human CRP transgenic mouse models find that CRP is pathogenic and can function as a mediator for AKI and CKD as mice overexpressing human CRP promote AKI and CKD. Mechanistically, CRP can promote AKI and CKD via NF-κB and Smad3-dependent mechanisms. We found that CRP can activate Smad3 signaling directly and cause AKI via the Smad3-p27-dependent G1 cell cycle arrest mechanism. Thus, targeting CRP-Smad3 signaling with a neutralizing antibody or Smad3 inhibitor can inhibit AKI. Key Messages: CRP acts not only as a biomarker but also as a mediator for AKI and CKD. CRP can activate Smad3 to induce cell death and cause progressive renal fibrosis. Thus, targeting CRP-Smad3 signaling may represent a promising therapy for AKI and CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.